Introduction
Heparin is a mixture of glycosaminoglycan chains that produces anticoagulant activity, a property discovered in the 1930s. These chains vary in molecular weight from approximately 3000 to 30 000 d. 1 Heparin chains of varying molecular weight exhibit varying pharmacologic effects. [2] [3] [4] For example, it is well appreciated that there is a minimal heparin chain length required to promote thrombin inhibition. 5 In addition, pharmacokinetic behavior is influenced by chain length, with shorter heparin chains exhibiting a higher bioavailability and slower clearance than larger chains. 1 Such differences in pharmacokinetic and pharmacologic effects have led to the pharmaceutical development and clinical acceptance of the low-molecular-weight heparins (LMWHs). 6 For heparin chains of a given size, there is another level of heterogeneity in that the components that make up the heparin chains are not identical. Heparin chains may contain iduronic or glucuronic acid as well as exhibit differential patterns of sulfation and acetylation. 7 The most notable illustration of this is the presence of a particular 3-O sulfate group required for interaction of heparin with antithrombin (AT). 8 This 3-O sulfate group is present in only a small percentage of heparin chains.
The rationale for the development of LMWHs was based on the belief that anti-Xa activity supported efficacy whereas anti-IIa activity was responsible for bleeding effects. In reality, the activity of LMWHs is much more complex, and anti-Xa and anti-IIa activities are not sufficient to completely explain their in vivo actions. Low-molecular-weight heparins have been shown in a number of clinical trials to be safe and effective in the prevention and treatment of venous thrombosis. 9 More recently, the effectiveness of LMWHs for the treatment of patients with pulmonary embolism or acute coronary syndrome (ACS) has been established. 10, 11 These drugs are now considered the standard of care for the clinical management of venous thromboembolism (VTE). As the patents on the original LMWHs expire, significant interest in producing generic versions has developed.
To streamline and balance the economic, scientific, and ethical issues associated with the development of generic LMWHs have been topics of discussion at peer group organizations such as the 
How Are Generic LMWHS Drugs Defined?
There is debate as to whether published specifications for LMWHs, currently limited to antifactor Xa potencies and molecular weight distributions found in product patents and pharmacopoeial descriptions, are sufficient to define ''sameness'' between generic and innovator LMWHs. It is unfortunate, though not entirely unexpected, that much of the discussion on generic LMWHs is focused on economic concerns, with manufacturers of branded LMWHs protecting their investment and recommending complete characterization of their substances, while potential suppliers of generic LMWHs prefer to apply the current definition of generic drugs as it is seen as the lowest barrier to regulatory approval. 12 This ongoing debate is centered on the fact that LMWHs are complex biological products and not simple, homogeneous small molecule drugs. For small molecule drugs, generic equivalents must contain the same active ingredient (ie, exhibit identical structure) and exhibit a comparable potency and pharmacokinetic/pharmacodynamic (PK/PD) profile. To be considered bioequivalent, bioavailability cannot be more than 25% lower or 25% greater than the innovator product. 13 One reason such a definition is difficult to apply to the LMWHs is that there is no chemical means of determining circulating blood levels of the drug. Rather, pharmacokinetic analysis is typically based on pharmacodynamic measures (eg, anti-Xa activity). Bioequivalance in terms of anti-Xa activity, however, does not ensure identical pharmacokinetic behavior in terms of other biological activities. Studies carried out with a variety of heparins and LMWHs have demonstrated distinct differences in pharmacokinetic parameters (volume of distribution, clearance, etc) when circulating anti-Xa, anti-IIa, or tissue factor pathway inhibitor (TFPI) levels are used to determine drug levels. 14 Pharmacopoeial definitions of potency (anti-Xa and anti-IIa activities) relate to largely ATdependent actions. Another difficulty in applying this definition of ''generic'' is that, like unfractionated heparin (UFH), not all the biological functions of the LMWHs relate to their ability to bind AT. Overall charge density is an important determinant for the affinity of heparin chains to a variety of proteins and growth factors, including heparin cofactor II and platelet factor 4 (PF4) and for the release of TFPI. 15 It is well appreciated that microchemical changes in the heparin molecule can affect its biological activity. More specifically, a number of sulfate groups are known to be critical for heparin's highaffinity interaction with AT. 16, 17 Chemical properties of a heparin chain govern its pharmacologic properties.
Additional complications lies in the limitations of current technology to accurately and efficiently identify all the components that makes up a LMWH. A heparin or LMWH preparation contains oligosaccharide chains of varying length. For any given chain length, there is further heterogeneity among the disaccharide building blocks in terms of fine chemical structure (ie, sulfation pattern). Although advances have been made in the structural characterization of heparin using nuclear magnetic resonance (NMR), mass spectrometry, and enzymatic digestion, 18 it is unclear whether such techniques can be practically applied to complex mixtures of oligosaccharide chains. We are also limited in our knowledge of how each component of the heparin mixture contributes to the overall clinical effect of the drug. Thus, setting appropriate ranges to define chemical equivalence is difficult.
Being heterogeneous in nature and with the relative proportion of different circulating components being dosage, route, and time dependent, the circulating amount of pharmacoactive components vary widely.
Regulatory Considerations
Over the past several years, a number of applications have been submitted to the US Food and Drug Administration (FDA) seeking marketing approval for generic versions of enoxaparin and dalteparin. The delay in responding to these applications has in large part been because of the lack of a logical pathway defining how such products (termed follow-on biologics or biosimilars) should be evaluated. Recently, a bill entitled ''Biologics Price Competition and Innovation Act of 2007'' was introduced into the US Senate for consideration. This bill proposes a process by which biosimilar products could be approved. Under this bill, a product would be considered biosimilar based on analytical data demonstrating that the product is '' . . . highly similar to the reference product not with standing minor differences in clinically inactive components,'' animal data and clinical studies assessing immunogenicity, and PK/PD sufficient to demonstrate safety, purity, and potency in 1 or more conditions for which the branded drug is licensed. Additional provisions are made to demonstrate interchangeability. Approval of a biosimilar could not be made before 12 years after the date of approval of the branded product. The first interchangeable biological product would gain 1 year of marketing exclusivity.
According to this bill, to be approved, biosimilars will have to be ''highly similar to the reference product not withstanding minor differences in clinically inactive components.'' Two questions are apparent here. First, how will ''highly similar'' be defined? Will it be based solely on anti-Xa and anti-IIa activities, or will other parameters such as those outlined above be taken into account? Regardless of what parameters are selected, what range of activity will be considered acceptable? Generic drugs are considered bioequivalent if their potency is within the range of 25% less to 25% more activity compared to the reference drug. Will this range be acceptable for all indications for which LMWHs are indicated? The second important point here concerns whether we truly know what the clinically inactive (or for that matter active) components of heparin are and whether these are the same for all indications for which LMWH is used.
The European Medicines Agency (EMEA) has recently issued draft guidelines for the development of biosimilar LMWHs. These guidelines require an extensive characterization of the biosimilar product with both preclinical and clinical testing. Preclinically, the LMWHs would need to show comparable activity in a series of in vitro bioassays as well as in terms of pharmacodynamic activity in appropriate animal models. Clinical studies would also need to be carried out. Comparable absorption and elimination will need to be demonstrated in terms of conventional surrogate markers (anti-IIa, anti-Xa, and global clotting test . . . ) in a randomized crossover study in healthy volunteers. Clinical efficacy and safety are to be evaluated in an indication with high VTE risk such as major orthopedic surgery. For both the PK/PD and efficacy/safety studies, strict equivalence design with properly defined equivalence margins determined a priori must be followed. Demonstration of comparable efficacy and safety may allow for extrapolation to other. 19, 20 
Current Generic Versions of LMWH
A number of generic versions of enoxaparin are being used in Southeast Asia and South America. These include low-molecular-weight heparins marketed under the names of Cutenox Lupenox, Dripanina, Clenox, Lopararin, Dilutol, and Omatex. Additionally, several manufacturers have submitted applications to the US FDA to obtain marketing approval for generic versions of enoxaparin in the United States. 21, 22 Data from several studies comparing the pharmacologic effects of these various LMWHs have been reported at various scientific meetings. 19, 20, [23] [24] [25] [26] It has been shown, for instance, that different generic versions of enoxaparin are differentially digested by heparinase, implying that there may be subtle structural differences in some of the oligosaccharides making up the product. Some of these differences may be carried over from structural differences in the parent heparin. Pharmacologically, it has been shown that generic versions of enoxaparin can be developed with comparable anti-Xa and anticoagulant potencies. Differences become apparent when other parameters are evaluated such as TFPI release, thrombin activatable fibrinolytic inhibitor (TAFI) activation, and effects in thrombin generation assays. Additionally, when these agents are evaluated using common animal models of the thrombosis and hemorrhage, differences in effectiveness are observed. As with the family of innovator LMWHs, the circulating level of anti-Xa activity observed following the administration of the various generic versions of enoxaparin did not necessarily correlate with the observed antithrombotic activity.
Citizen's Petition and Supplements From the Innovators
In the United States, anyone may request or petition FDA to change or create an Agency policy or regulation under 21 CFR Part 10.30. This process can be used to express concerns over the sameness of the generic versions of biologic drugs.
As part of the ongoing debate regarding how a ''generic'' LMWH will be considered equivalent to the originator, Sanofi-Aventis had submitted a Citizen's Petition and several subsequent supplements to the US FDA, which describe preclinical studies performed to identify specific structural features, so-called fingerprints, of enoxaparin. Additionally, these documents attempt to link biologic effects to the presence of the fingerprints.
It is logical that with the evolution of analytical techniques, a more precise structural characterization of enoxaparin can be carried out now than when the enoxaperin was first introduced almost 20 years ago. In spite of these developments in analytical technologies, it appears that about 30% (according to the manufacturer) of the polysaccharide chains comprising enoxaparin have yet to be identified.
The Citizen's Petition describes a number of previously unknown structural characteristics of enoxaparin. It has been found, for instance, that the manufacturing process results in the generation of saccharide chains containing an odd number of saccharide units. Such saccharide chains are formed when glucosamine moieties are removed from the oligosaccharide at its reducing end. The process also results in the formation of galactouronic acid moieties in the polysaccharide sequences.
The manufacturing process for enoxaparin results in the formation of a bicyclic 1,6-anhydro ring structure at the reducing end of all oligosaccharides bearing 6-0-sulfo groups on the glucosamine moiety (approximately 15%-25% of the oligosaccharide chains comprising enoxaparin) To date, this structure is unique and has not been found in other clinically used LMWHs.
It has been understood for many years that a specific 3-O sulphated pentasaccharide sequence in heparin is required for its binding to AT. In the Citizen's Petition and Supplements, Sanofi-Aventis presents data describing other oligosaccharides found in enoxaparin that include the classical AT-binding sequence as well as polysaccharides that do not contain this sequence but that specifically bind to AT with affinities similar to the others. From these data, it appears that the classical AT-binding sequence may not be the only structural motif in enoxaparin that binds to AT with high affinity. To what extent the presence of these different AT-binding oligosaccharides is unique to enoxaparin and its production method is unknown.
The antithrombotic activity of enoxaparin, as well as other low-molecular-weight heparins, is related to both AT-mediated inhibition of coagulation proteases and to other non-AT-mediated mechanisms. The Citizen's Petition and Supplements also attempt to link structural fingerprints with biologic activities. Along these lines, most of the reported studies have focused on the effect of the 1,6-anhydro ring.
The influence of the 1,6-anhydro ring on the anticoagulant activity of enoxaparin has been determined by comparison of the activity of enoxaparin (15%-25% 1,6-anhydro ring) to that of 2 LMWHs similar to enoxaparin but containing either a lesser amount (less than 7%) of 1,6-anhydro or a much higher amount (40%-50%). No statistically significant difference between these LMWHs was observed in the activated partial thromboplastin time (aPTT), prothrombin time, thrombin generation, anti-Xa, anti-IIa, or thromboelastographic assays. However, when hexadecasaccharide fractions with either normal or low 1,6-anhydro content were compared, it was observed that the fraction with low 1,6anhydrocontent had a greater anticoagulant activity than the fraction with normal content.
No relationship between the 1,6-anhydro structure content and inhibition of factor VIIa generation was found. However, the concentration of ATbinding sites within enoxaparin influences FVIIa generation inhibition. This is illustrated by the fact that pure octasaccharides bearing normal amounts of AT-binding sites show greater inhibition of FVIIa generation compared to compounds that contain only smaller amounts of AT-binding oligosaccharides. The proportion and structure of AT-binding sites is a function of the manufacturing process.
Tissue factor pathway inhibitor released from endothelial cells is an important regulatory mechanism of blood coagulation. After injection of either standard heparin or enoxaparin, the circulating level of TFPI is significantly increased. It has been shown that TFPI contributes to the anticoagulant/antithrombotic activity of heparin and enoxaparin. The influence of enoxaparin components and structures on TFPI release has been tested in conditions of endothelial cell TFPI release inhibition induced by the bacterial endotoxin lipopolysaccharide (LPS).
The reversal of this inhibition shows the ability of compounds to release TFPI. This study demonstrated that both polysaccharide chain length and 1,6-anhydro ring structure content affect enoxaparin's reversal of TFPI inhibition. For any given chain length, reversal is stronger for oligosaccharides containing the higher concentration of the 1,6-anhydro structure.
Enoxaparin is indicated for prophylaxis of deep vein thrombosis (DVT) during abdominal, hip, and knee replacement surgeries and in patients with thromboembolic risk because of severely restricted mobility and for prophylaxis of ischemic complications associated with unstable angina and non-Q-wave myocardial infarction. Inflammation plays an important role in the pathogenesis of these conditions. For example, inflammation may cause unstable angina by promoting rupture and erosion of vulnerable coronary plaques.
Inflammation plays a crucial role in the pathology of myocardial ischemia and unstable angina and in the development of atherosclerotic lesions. Antiinflammatory properties of enoxaparin have been demonstrated through in vitro (interaction with P-selectin) and in vivo (animal) studies (inhibition of neutrophil accumulation at myocardial infarct site). The Citizen's petition data from preliminary studies evaluated the impact of 1,6-anhydro on nonanticoagulant biologic effects. In particular, it was found that there was a content-dependent inhibition of the contact-kinin system. Additionally, it was shown that altering the 1,6-anhydro content (either increasing or decreasing) resulted in reduced ability to inhibit LPS-induced nitrite/nitrate levels and to inhibit complement activation. It is unclear whether the observed 3-fold difference in anti-inflammatory potency is significant in relation to a clinically relevant end point, particularly when considering that most cardiovascular patients are also being treated with other anti-inflammatory drugs (ie, aspirin).
Effects of enoxaparin on the vasculature were also studied. One component of the pathophysiology of unstable angina and non-Q-wave myocardial infarction is artery enlargement related to smooth muscle cell (SMC) proliferation. It has been found that the 1,6-anhydro ring increases enoxaparin's inhibitory action on SMC proliferation. What is not clear from these studies is the clinical relevance of the observation. In these studies, cell cultures were treated for a period of 7 days with media supplemented with various LMWHs. Presumably, the LMWH level remained fairly constant, or at least more constant than would be observed following once of twice daily dosing. The rationale for looking at a SMC effect of enoxaparin is that SMC proliferation is a partial cause of the vascular pathology associated with atherosclerosis, hypertension, and restenosis. In patients with such diseases, however, the vascular pathology is already developed at the time enoxaparin therapy would be initiated.
Angiogenesis is a process involving endothelial cell proliferation, which can ameliorate diseases characterized by microvascular insufficiency such as ischemic heart disease, where hypoxic myocardium needs formation of new vessels to limit ischemic injury. Acidic fibroblast growth factor (aFGF) is able to induce neoangiogenesis in the ischemic myocardium. It has been shown that the 1,6-anhydro ring optimizes enoxaparin's interaction with aFGF. Testing another member of the FGF family (basic fibroblast growth factor [bFGF]), it was found that oligosaccharides isolated from enoxaparin inhibited bFGF induced endothelial cell proliferation more potently when they do not contain the 1,6-anhydro ring than when they do contain it.
The Citizen's Petition and subsequent supplements provide food for thought as to other potential biologic actions of LMWHs that may explain the clinical effects of the drug. As such, the concepts brought up in the Citizen's Petition may drive research into a better understanding of the biologic effects of LMWHs.
The Citizen's Petition and subsequent supplements provide data on previously unidentified structural features of oligosaccharides that make up enoxaparin. As analytical techniques evolve, it is not surprising that a clearer picture of the structural makeup of enoxaparin is now available. It seems reasonable that the best (and most complete) data available should be used to determine structural similarity. Despite advances in analytical techniques, a considerable amount of oligosaccharides remain unidentified (*30% according to the manufacturer). Having more points of reference in the comparison of branded and biosimilar LMWHs will increase the confidence that the unidentified fraction is also the same.
As far as the development of generic LMWHs is concerned, the data presented in the Citizen's Petition provide some interesting direction but is far from conclusive in demonstrating the uniqueness of enoxaparin. A major drawback of the Citizen's Petition is that the data provided are not published and is largely driven from internal reports. For the most part, the findings reported on have not been independently verified nor have they undergone the peer review process. One exception to this is the demonstration that the amount of 1,6-anhydro in a given LMWH preparation affects anticoagulant activity measured in vitro. 19 It is noteworthy that on one hand claiming that enoxaparin has not been completely characterized, on the other, LMWHs containing variable amounts of 1,6-anhydro are judged to be similar based on anti-Xa potency, molecular weight, and anti-Xa:anti-IIa ratio. Because the formation of the 1,6anhydro group is a product of the depolymerization process and is dependent on reaction time, pH, and temperature, the obvious question is whether other structural changes have also occurred. With a significant fraction of the oligosaccharides remaining uncharacterized, it may not be possible to determine whether the 1,6-anhydro group is solely responsible for the observed differences in activity. The studies that evaluated the impact of 1,6-anhydro on various biologic activities used LMWHs containing much lower or much higher amounts than found in commercial enoxaparin preparations. It seems unlikely that biosimilar preparations would differ by that much. It is likely that beside the 1,6-anhydromanno sugars, other characteristic changes may also occur during the production of enoxaparin.
The US FDA has identified the immunogenicity of LMWHs as an important criterion to differentiate and/or demonstrate the bioequivalence of generic LMWHs and branded products. The incidence of heparin-induced thrombocytopenia (HIT) is rare with the use of LMWHs. Up to 20% of patients treated with LMWHs, however, generate antibodies to heparin-PF4 complexes, which have an unknown pathological function. The agency has determined that if a generic product has a similar composition and proportion of oligosaccharide components as the branded product, then the generic product should exhibit a similar quantitative and qualitative immunogenic profile. Sanofi-Aventis' Citizen's Petition does not include any studies to assess the impact of the 1,6-anhydro ring structure on immunogenicity. The formation of complexes between PF4 and heparin oligosaccharides is a charge-mediated reaction. The loss of 6-O sulfate groups during the formation of the 1,6-anhydro ring may affect this interaction, resulting in differential response.
Also missing from the discussion on the characterization of generic versions of enoxaparin is the impact of batch-to-batch variability on the ultimate clinical effect of the drug. Little has been presented as to the extent of variation in the innovator product; this is important framework for the valid evaluation of differences between generic and innovator products and between different generic products. Relatively little is known about the effect that variation in starting material has on the final LMWH product and to what extent the variations in UFH can be compensated for by tweaking process variables.
Although most the points raised in the Citizen's Petition and other academic studies are important from the standpoint of understanding exactly how heparins work, we have little knowledge as to how variations in these parameters, whether it be 1,6-anhydro content, or anti-inflammatory actions or TFPI release, affect clinically relevant end points. Further studies along these lines should be carried out not only to develop guidelines for LMWH equivalence but also to obtain a clearer understanding of the hemostatic process, in general. Thrombotic disorders represent a multifactorial pathogenic event, which can further be differentiated based on the arterial, venous, and microvascular sites. Being polypharmocologic agents, the LMWHs target various sites to produce their therapeutic effects. Thus, the composition of these agents plays a crucial role, and to expect identical performance, both the generic and branded product should have the same composition. Almost 70% of the oligosaccharide components do not exhibit any affinity to AT; however, this component is able to interact with numerous endogenous proteins including growth factors, cytokines, macromolecules, and cellular sites. Most of these interactions remain unexplored at this time. Therefore, it is crucial to include multiparametric data to demonstrate the sameness of these agents. This of course is dependent on the clinical indications for which the generic versions of LMWHs are to be considered.
Summary
Low-molecular-weight heparins are complex drug products that are made up of a large number of oligosaccharide chains and produce a number of biologic effects. Within the class, each LMWH exhibits a different molecular weight profile and biologic potency in terms of anti-Xa and anti-IIa activities. Each LMWH is used at a product-specific dose and substitution of one LMWH for another on a unit-per-unit or mg-per-mg basis is not recommended. Although LMWHs are considered ''gold standards'' for the treatment of VTE and ACS, it remains unclear to this day how a given biological effect contributes to their overall therapeutic effects.
Generic versions of LMWHs under the newly defined class of biosimilars are being developed. Although the potential for lower cost therapy is attractive, determining whether a generic version is in fact equivalent to the originator has been difficult for a number of reasons. Heterogeneity among the component oligosaccharides that make up a given LMWH makes it difficult to demonstrate structural similarity. The current data show that although LMWHs can exhibit the same mean molecular weight, microstructural differences can be present as indicated by the differential susceptibility to heparinase digestion. Such microstructural differences likely affect interaction with proteins and cells. 20 As structural differences in the parent UFH likely carry over to the LMWH product, specifications for starting material will likely be beneficial.
Although LMWHs are typically compared in terms of their AT-dependent actions (anti-Xa and anti-IIa activity), they produce other effects that contribute to their antithrombotic activity. Current data show that while comparable anticoagulant and antiprotease activities can be observed with the generic LMWHs, they can still differ in other ways. From the current study, differences in the effect of generic LMWHs on thrombin-induced platelet activation, in the pharmacodynamics of TFPI release, and in the activation of TAFI are 3 examples.
The important issue to be addressed is whether chemical and biologic differences between generic LMWHs observed in vitro affect the pharmacologic behavior and, thus, the clinical safety/efficacy of the agent. Guidelines for the acceptance of generic LMWHs should consider multiple parameters, including source material and pharmacologic potency evaluations extending beyond conventional anti-Xa and anti-IIa measurements and molecular weight distribution. Specific structural attributes in each product and their impact on overall biologic profile should be considered. In vivo equivalence studies including animal studies and qualified human trials may be required to validate the biosimilarity of generic and branded LMWHs.
The ongoing regulation of generic drugs represents a major challenge for the regulatory bodies such as the US FDA and the EMEA. Because generic drugs account for over 60% of all US prescriptions for drugs and are sold at substantially low price, this option for drugs such as the LMWHs appears very attractive. However, the complexity of these drugs and their endogenous interactions lead to complex responses such as the generation of antibodies, and their long-term impact on the safety and efficacy poses some difficult questions. Therefore, the current guidelines to approve generic drugs are inadequate for the regulatory approval of LMWHs and related drugs. Additional guidelines consistent with the advancements and technology and drug evaluation procedures are warranted at this time. Until then, a generic interchange between complex and hybrid biologic and chemical drugs such as the LMWHs is not recommended.
